Skip to content

Study · Not a test of the peptide alone · 2017

6 results

Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.

Nauck MA, Kahle M, Baranov O, Deacon CF, Holst JJ

Diabetes, obesity & metabolism9 Nov 2016Cited by 36 (Europe PMC)

PMID27709794 (opens in a new tab)DOI10.1111/dom.12802 (opens in a new tab)PepBankPUB-27709794
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on liraglutide, adding sitagliptin did not significantly change glucose excursions after a mixed meal versus placebo.

    In plain wordsIn adults with type 2 diabetes on liraglutide, adding sitagliptin did not significantly change blood glucose after a meal compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeGlucose excursion (incremental AUC)
    Study

    n = 16

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    AUC glucose
    319 mmol.L-1.min-1
    placebo
    AUC glucose
    315 mmol.L-1.min-1
    sitagliptin

    Source sentences

    Summary
    Glucose (AUCglucose 319 ± 30 [placebo] vs 315 ± 18 mmol.L-1 .min-1 [sitagliptin], Δ 7 [95% confidence interval -50 to 63] mmol.L-1 .min-1 ), insulin, C-peptide and glucagon concentrations were not affected significantly by sitagliptin treatment ( P = .60-1.00).
    1 context sentence
    Summary · context
    A total of 16 patients with type 2 diabetes treated with metformin and liraglutide (1.2 mg/d for ≥2 weeks) were randomized (sealed envelopes), within a cross-over design, to be studied on two occasions, after an overnight fast, with (1) sitagliptin (100 mg orally) and (2) placebo (patients and care…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on liraglutide, adding sitagliptin did not significantly change insulin concentrations versus placebo.

    In plain wordsIn adults with type 2 diabetes on liraglutide, adding sitagliptin did not significantly change insulin levels compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeInsulin concentration
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    insulin, C-peptide and glucagon concentrations were not affected significantly by sitagliptin treatment ( P = .60-1.00).
    1 context sentence
    Summary · context
    A total of 16 patients with type 2 diabetes treated with metformin and liraglutide (1.2 mg/d for ≥2 weeks) were randomized (sealed envelopes), within a cross-over design, to be studied on two occasions, after an overnight fast, with (1) sitagliptin (100 mg orally) and (2) placebo (patients and care…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on liraglutide, adding sitagliptin did not significantly change C-peptide concentrations versus placebo.

    In plain wordsIn adults with type 2 diabetes on liraglutide, adding sitagliptin did not significantly change C-peptide levels compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeC-peptide concentration
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    insulin, C-peptide and glucagon concentrations were not affected significantly by sitagliptin treatment ( P = .60-1.00).
    1 context sentence
    Summary · context
    A total of 16 patients with type 2 diabetes treated with metformin and liraglutide (1.2 mg/d for ≥2 weeks) were randomized (sealed envelopes), within a cross-over design, to be studied on two occasions, after an overnight fast, with (1) sitagliptin (100 mg orally) and (2) placebo (patients and care…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on liraglutide, adding sitagliptin did not significantly change glucagon concentrations versus placebo.

    In plain wordsIn adults with type 2 diabetes on liraglutide, adding sitagliptin did not significantly change glucagon levels compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeGlucagon concentration
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    insulin, C-peptide and glucagon concentrations were not affected significantly by sitagliptin treatment ( P = .60-1.00).
    1 context sentence
    Summary · context
    A total of 16 patients with type 2 diabetes treated with metformin and liraglutide (1.2 mg/d for ≥2 weeks) were randomized (sealed envelopes), within a cross-over design, to be studied on two occasions, after an overnight fast, with (1) sitagliptin (100 mg orally) and (2) placebo (patients and care…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneRandomized controlled trialMechanism

    In adults with type 2 diabetes on liraglutide, adding sitagliptin increased intact GLP-1 concentrations by 78.4% versus placebo.

    In plain wordsIn adults with type 2 diabetes on liraglutide, adding sitagliptin raised intact GLP-1 levels compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseIntact GLP-1 concentration
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Measurements

    Intact GLP-1 increase
    78.4%
    sitagliptin

    Source sentences

    Summary
    Intact glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) concentrations were augmented by sitagliptin, by 78.4% and 90.2%, respectively (both P < .0001).
    1 context sentence
    Summary · context
    A total of 16 patients with type 2 diabetes treated with metformin and liraglutide (1.2 mg/d for ≥2 weeks) were randomized (sealed envelopes), within a cross-over design, to be studied on two occasions, after an overnight fast, with (1) sitagliptin (100 mg orally) and (2) placebo (patients and care…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Liraglutide aloneRandomized controlled trialMechanism

    In adults with type 2 diabetes on liraglutide, adding sitagliptin increased intact GIP concentrations by 90.2% versus placebo.

    In plain wordsIn adults with type 2 diabetes on liraglutide, adding sitagliptin raised intact GIP levels compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseIntact GIP concentration
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Measurements

    Intact GIP increase
    90.2%
    sitagliptin

    Source sentences

    Summary
    Intact glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) concentrations were augmented by sitagliptin, by 78.4% and 90.2%, respectively (both P < .0001).
    1 context sentence
    Summary · context
    A total of 16 patients with type 2 diabetes treated with metformin and liraglutide (1.2 mg/d for ≥2 weeks) were randomized (sealed envelopes), within a cross-over design, to be studied on two occasions, after an overnight fast, with (1) sitagliptin (100 mg orally) and (2) placebo (patients and care…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.